Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemThe evolution of poxvirus vaccinesMalaria vaccine clinical trials: what's on the horizonThe March Toward Malaria VaccinesHuman vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureA PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Recent advances in recombinant protein-based malaria vaccines.Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Progress and prospects for blood-stage malaria vaccinesGerminal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.The march toward malaria vaccines.Recombinant modified vaccinia virus Ankara-based malaria vaccines.Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.Development of replication-deficient adenovirus malaria vaccines.A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage ChallengeInnate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.Analysis of the immune response of a new malaria vaccine based on the modification of cryptic epitopes.Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.Assessment of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines.Simian adenoviruses as vaccine vectors.Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cellsCXCR3 T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against MalariaMalaria Vaccines: Recent Advances and New Horizons
P2860
Q24273364-C5854874-C309-49DE-BDB3-BFF300C8BB6EQ26700012-260FE1E5-F26E-45A9-BD41-45282A651DFEQ26995905-0FE1468A-132D-4DA0-9325-507C026A2881Q28083110-7FE0D143-A42D-45B5-ADE3-37FF6327E525Q28084325-FB4A0536-CB32-49A6-80ED-2F2071C98704Q33798074-E22DEE7C-2878-4C81-93F8-E639A2AC04D9Q33835382-6AE6DC5F-EB5D-48D0-9E94-895F8EC357B1Q34257253-2E8F70B4-968B-488E-B506-EBAF99B52A11Q34978590-DED9E7B6-F365-4A42-86AD-ACDDB2E110B8Q36394177-A544E14F-1764-441D-9D03-EDCD66963942Q36394182-5A590ACC-D31C-400F-97BA-8DA40E193248Q36871970-51459016-8CE0-4B81-91F3-4E4E7E49B761Q37025030-72416F93-045B-494A-B47A-35E410DF8106Q37153663-416CB49B-9060-4881-9961-BC9AE08ABDF4Q38577638-9590586B-4718-4C24-8166-1C366A5D650AQ38618898-26024DB5-7DF0-4E5F-BF9E-ED7B490FC88FQ38718229-02F51A03-C29C-4EF7-BF06-749A6707BC45Q38949194-7AC32ACB-3FA1-4C54-A1A5-7D1F548EF4B0Q39315273-31D5893D-3190-4E05-ACA9-15A87D06416FQ39748955-5D8CF90B-D698-4628-98D2-1C1634C57602Q40809441-AF051D88-C1A9-44B9-8096-5E8ECC8C0FBDQ47576664-F741126D-12AB-4E4E-9237-61C06553FE14Q47607706-7DB23581-8ADC-4017-A957-6CB1B5CDEE8FQ49730085-A6429DAD-FA2F-45A5-8389-D363FE4C4893Q54531277-F438182F-3B4F-41DD-BD8B-89EA054C2380Q56342201-DD5CC2A8-A0A6-4226-9CDC-EA5C280CE77CQ56357275-C8E67FF2-477E-4569-8923-7F6725E884E8Q56362064-E129C9A2-7B8B-4947-B5AB-3040E98D1425
P2860
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Combining viral vectored and p ...... on a phase 1a clinical trial.
@ast
Combining viral vectored and p ...... on a phase 1a clinical trial.
@en
Combining viral vectored and p ...... on a phase 1a clinical trial.
@nl
type
label
Combining viral vectored and p ...... on a phase 1a clinical trial.
@ast
Combining viral vectored and p ...... on a phase 1a clinical trial.
@en
Combining viral vectored and p ...... on a phase 1a clinical trial.
@nl
prefLabel
Combining viral vectored and p ...... on a phase 1a clinical trial.
@ast
Combining viral vectored and p ...... on a phase 1a clinical trial.
@en
Combining viral vectored and p ...... on a phase 1a clinical trial.
@nl
P2093
P2860
P50
P356
P1433
P1476
Combining viral vectored and p ...... on a phase 1a clinical trial.
@en
P2093
Alfredo Nicosia
Alison M Lawrie
Daming Zhu
Daniel Gw Alanine
Eleanor Berrie
Ian D Poulton
Joseph J Illingworth
Kathryn H Milne
Prateek Choudhary
Sarah Moyle
P2860
P304
P356
10.1038/MT.2014.157
P50
P577
2014-08-26T00:00:00Z